Can GLP-1s Transform Addiction Treatment?

GLP-1 medications are changing how we think about addiction. This week, an addiction medicine physician outlines the emerging science linking these drugs to reduced cravings, improved impulse control and recovery support, and shares why they may represent a major shift in addiction treatment and prevention. In this episode, Mohini talks with Dr. Steven Klein about the growing evidence that GLP-1s may help treat addiction by reducing cravings and interrupting addictive behaviors. Drawing on both research and clinical experience, Dr. Klein explores the connection between obesity, substance use disorders and the brain’s reward system. He also discusses what these medications could mean for alcohol use disorder, impulse control, stigma reduction and the future of recovery care as this rapidly evolving field continues to develop. Listeners will learn: How GLP-1s may reduce cravings and substance use by acting on the brain's reward pathways. What current research reveals about GLP-1s and alcohol use disorder, as well as emerging evidence across other substances. Why concepts like agency, impulse control and dopamine regulation are becoming increasingly important in addiction treatment. Dr. Steven Klein is a compassionate and highly accomplished physician-scientist specializing in addiction medicine. Dr. Klein is dedicated to advancing innovative, evidence-based approaches to support recovery for teens, young adults and individuals facing relapse challenges. Follow for weekly conversations shaping mental health and substance use care.